| Sky R Blue, MD | |
|
125 E Idaho St, Suite 203, Boise, ID 83712-6212 | |
| (208) 338-0148 | |
| (208) 336-4027 |
| Full Name | Sky R Blue |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 35 Years |
| Location | 125 E Idaho St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659365575 | NPI | - | NPPES |
| 000010000484 | Other | ID | REGENCE BLUE SHIELD OF ID |
| J1676 | Other | ID | BLUE CROSS OF IDAHO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | M7398 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| St Luke's Nampa Medical Center | Nampa, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Medical Center - Nampa | Nampa, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Full Circle Health, Inc. | 6709986797 | 93 |
| Sawtooth Epidemiology And Infectious Diseases P.c. | 8628242997 | 9 |
| St Lukes Clinic-treasure Valley Llc | 4981878402 | 968 |
News Archive
A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer.
A case in Uganda of a woman bleeding to death while giving birth "underscores an unintended consequence of global health aid," a Globe and Mail editorial writes, adding that "in some parts of sub-Saharan Africa, a reverse trend is under way; for every $1 of development assistance for health, governments have reduced their spending," according to a study from the Institute for Health Metrics and Evaluation at the University of Washington.
Already the world's leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.
› Verified 4 days ago
| Entity Name | Full Circle Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841490075 PECOS PAC ID: 6709986797 Enrollment ID: O20070924000618 |
News Archive
A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer.
A case in Uganda of a woman bleeding to death while giving birth "underscores an unintended consequence of global health aid," a Globe and Mail editorial writes, adding that "in some parts of sub-Saharan Africa, a reverse trend is under way; for every $1 of development assistance for health, governments have reduced their spending," according to a study from the Institute for Health Metrics and Evaluation at the University of Washington.
Already the world's leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.
› Verified 4 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer.
A case in Uganda of a woman bleeding to death while giving birth "underscores an unintended consequence of global health aid," a Globe and Mail editorial writes, adding that "in some parts of sub-Saharan Africa, a reverse trend is under way; for every $1 of development assistance for health, governments have reduced their spending," according to a study from the Institute for Health Metrics and Evaluation at the University of Washington.
Already the world's leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.
› Verified 4 days ago
| Entity Name | Sawtooth Epidemiology And Infectious Diseases P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225326515 PECOS PAC ID: 8628242997 Enrollment ID: O20111122000918 |
News Archive
A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer.
A case in Uganda of a woman bleeding to death while giving birth "underscores an unintended consequence of global health aid," a Globe and Mail editorial writes, adding that "in some parts of sub-Saharan Africa, a reverse trend is under way; for every $1 of development assistance for health, governments have reduced their spending," according to a study from the Institute for Health Metrics and Evaluation at the University of Washington.
Already the world's leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sky R Blue, MD 125 E Idaho St, Suite 203, Boise, ID 83712-6212 Ph: (208) 338-0148 | Sky R Blue, MD 125 E Idaho St, Suite 203, Boise, ID 83712-6212 Ph: (208) 338-0148 |
News Archive
A major breakthrough by scientists at Queen's University Belfast could lead to more effective treatments for throat and cervical cancer.
A case in Uganda of a woman bleeding to death while giving birth "underscores an unintended consequence of global health aid," a Globe and Mail editorial writes, adding that "in some parts of sub-Saharan Africa, a reverse trend is under way; for every $1 of development assistance for health, governments have reduced their spending," according to a study from the Institute for Health Metrics and Evaluation at the University of Washington.
Already the world's leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) is capitalizing on its expertise to deliver a broader range of validated molecular biology products. Research and development for these products will now be performed in a newly built facility in Redwood City, California.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
A new brace that maintains correction for clubfoot, a birth defect in which the foot is turned in toward the body, has shown better compliance and fewer complications than the traditional brace used to treat the condition.
› Verified 4 days ago
Dr. Jennifer A Hofstra, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 757-446-8920 Fax: 757-446-5242 | |
Dr. James Robert Polk, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-3104 | |
Dr. Michael Frederic Krug, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St, # 111, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1319 | |
Derrel V Walker, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 208-367-7350 Fax: 208-367-3951 | |
Dr. Janat E. O'donnell, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 500 W. Fort St., # 111, Boise, ID 83702 Phone: 208-422-1325 Fax: 208-422-1319 | |
Carl L Durning, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6094 W Emerald St, Boise, ID 83704 Phone: 208-367-6575 Fax: 208-367-6597 | |
Dr. Christopher J Goulet, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 6259 W Emerald St, Boise, ID 83704 Phone: 208-489-1900 Fax: 208-375-5286 |